MARATTO

article · Dental and Medical Problems

Effectiveness of the occlusal stabilization splint in the treatment of myogenous temporomandibular disorders: A systematic review

2026Open accessMohammed V University

Abstract

This systematic review aimed to assess the effectiveness of stabilization splints in the treatment of myogenous temporomandibular disorders (TMD).The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An electronic search was conducted in 2 databases - MEDLINE via PubMed and the Web of Science. The final search was conducted in May 2022.Ten randomized clinical trials (RCTs) were included. The total sample size was 539 participants, with a mean follow-up of 6 months. Four outcomes were assessed: pain reduction (10 studies); mouth opening improvement (5 studies); headache reduction (2 studies); and quality-of-life (QoL) improvement (4 studies). Most trials reported improvement in TMD symptoms in comparison with the baseline measures. Nevertheless, the overall quality of evidence was low due to moderate to high risk of bias and the small sample sizes.Given the limitations of the systematic review, occlusal stabilization splint therapy appeared to be effective in reducing the signs and symptoms of TMD. However, further large-scale prospective studies are needed to evaluate its long-term effectiveness.

Research topics

  • Temporomandibular Joint Disorders
  • Orthodontics and Dentofacial Orthopedics
  • Dysphagia Assessment and Management

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.17219/dmp/194530

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.